Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Sarcoma, Synovial 3Mesothelioma 3Sarcoma 2Rhabdoid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Small Cell Lung Carcinoma 1Mesothelioma, Malignant 1Hematologic Neoplasms 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 63Nivolumab 44atezolizumab 14Docetaxel 10Cyclophosphamide 10Paclitaxel 9Magnetic Resonance Spectroscopy 9Ipilimumab 9avelumab 8Specimen Handling 8durvalumab 7Radiosurgery 7Cetuximab 7spartalizumab 6Radiotherapy 6Immune Checkpoint Inhibitors 6Interleukin-2 5Carboplatin 5fludarabine 4cabozantinib 4Trastuzumab 4Sunitinib 4Psychiatric Rehabilitation 4Pemetrexed 4Oxaliplatin 4Fluorodeoxyglucose F18 4Everolimus 4Cisplatin 4Capecitabine 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × tazemetostat × Thoracic × Clear all
NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Ipsen

No longer available
GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡